ELAN - ELAN STOCK NEWS: BFA Law Alerts Elanco (NYSE:ELAN) Shareholders that it is Investigating the Company for Securities Fraud and Notifies Those with Losses to Contact Us | Benzinga

NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into Elanco Animal Health Incorporated (NYSE:ELAN) for potential violations of the federal securities laws.

If you invested in Elanco, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elanco-animal-health-incorporated.

Why Did Elanco's Stock Drop?

Elanco develops products to treat diseases in animals. Two of the most important treatments in the company's development pipeline are currently being reviewed by the U.S. Food and Drug Administration ("FDA"). The treatments are named Zenrelia, a drug for a type of dermatitis in dogs, and Credelio Quattro, which is a broad spectrum oral parasiticide covering fleas, ticks and internal parasites.
With respect to these treatments, the company stated that the FDA "has all data necessary ...

ELAN) Shareholders that it is Investigating the Company for Securities Fraud and Notifies Those with Losses to Contact Us>Full story available on Benzinga.com